Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 19 and up

Giving JW0104 together with C2402 for people with high blood pressure and high cholesterol

Official title: A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Run by JW Pharmaceutical · NCT06643130 · Data updated 2026-11-12

This study will test whether taking JW0104 with C2402 helps people who have both hypertension and dyslipidemia control their blood pressure and cholesterol.

More Hypertension trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages19 Years and up
SexAll
Enrollment162 (estimated)
SponsorJW Pharmaceutical
Industry-sponsored
Locations1 site (Seoul)
StatusRecruiting
StartedDecember 2, 2024
Main results expectedApril 2026
Study endsApril 2026
Registry record updatedSeptember 9, 2025
Trial IDNCT06643130 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults diagnosed with both hypertension and dyslipidemia who meet the study's specified blood pressure and LDL‑C thresholds are the intended candidates.

Probably not a fit

People who do not meet the study's specified blood pressure or LDL‑C levels, or who have exclusionary conditions, are unlikely to be eligible or to benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double‑blind, parallel Phase 3 trial planned at multiple centers to compare co‑administration of JW0104+C2402 versus JW0104+C2403 versus C2402 alone. Adults with both hypertension and dyslipidemia who meet the study's blood pressure and LDL‑C entry criteria will be enrolled and randomized to one of the three treatment arms. The trial measures efficacy outcomes related to blood pressure and lipid levels alongside safety and tolerability endpoints. Subjects who do not meet the specified msBP or LDL‑C thresholds are excluded, and dosing and visit schedules are standardized across sites.

Why it matters

Potential benefit: If successful, the combination could offer a new treatment option that improves both blood pressure and lipid control with an acceptable safety profile.

How similar studies have gone: Using combined antihypertensive and lipid‑lowering therapies is an established clinical approach, but these specific drug combinations are novel and have limited prior Phase 3 evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with hypertension and dyslipidemia

Exclusion Criteria:

* The subject not meet the specified msBP and LDL-C level

Where it's running

  • Gangdong Sacred Heart Hospital
    Seoul, South Korea
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.